A novel biomarker test to predict therapy selection for Inflammatory Bowel Disease

免疫介导性疾病，包括自身免疫性和炎症性疾病，是常见的、使人衰弱的和非常不同的：两个被诊断为相同疾病的患者可能遵循明显不同的临床过程。对于许多自身免疫性疾病，现在已经有了有效且往往昂贵的治疗方法。然而，它们引起的免疫抑制也会导致大量的副作用。因此，对临床分析的需求越来越大，使医生能够在正确的时间为正确的患者量身定做这些潜在的毒性免疫抑制疗法。然而，目前还没有可靠的临床或生物标记物分析来允许这些疾病的个性化治疗靶向。Predidice正在开发开创性的工具，用于指导免疫介导性炎症性疾病的治疗选择，其首个产品针对炎症性肠病(克罗恩病和溃疡性结肠炎)。为了充分实现炎症性肠病的个性化药物治疗目标，不仅需要证明预测，而且还需要证明，如果积极的治疗与预测将遵循侵袭性疾病病程的患者相匹配，临床结果可以得到改善。这将是这里提出的可行性研究的目标。

"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce also results in substantial side effects. Consequently, there is an increasing need for clinical assays that allow physicians to tailor these potentially toxic immunosuppressive therapies to the right patients at the right time. However, there are currently no robust clinical or biomarker assays that allow personalized therapeutic targeting in these diseases.PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with its first product addressing inflammatory bowel disease (both Crohn's disease and ulcerative colitis).In order to fully achieve the goal of personalized medicine in inflammatory bowel disease, it is necessary to demonstrate more than just prediction but also to show that clinical outcomes can be improved if aggressive therapy is matched to patients predicted to follow an aggressive disease course. This will be the goal of the feasibility study presented here."